Aboleris Pharma is a preclinical stage company, developing novel and unique therapeutic approaches to induce immune tolerance while preserving useful immune responses; with the aim to address significant medical unmet needs in patients with inflammatory, autoimmune and degenerative diseases.

Location: Belgium, Gosselies

Sound Contact: Bibhash Mukhopadhyay (Board Director) and Thomas Tan (Board Observer)

Read an interview with CEO Anne Meulemans

Web: https://aboleris-pharma.com

News: AbolerIS Pharma Announces €27 Million in Series A Financing to Advance its Novel Treatment Paradigm for Autoimmune and Inflammatory Diseases

English speaking media coverage of the Series A financing


* indicates required